Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?
Just over 50% of patients with advanced rectal cancer have a poor response to chemoradiotherapy with resultant poor outcomes. Professor Glimelius reviews the evidence base for defining such patients and the potential role, if any, of further treatment.